Skip to main content

Advertisement

SpringerLink
Log in

Synchronous Health Care Delivery for the Optimization of Cardiovascular and Renal Care in Patients with Type 2 Diabetes

  • Diabetes and Cardiovascular Disease (D Bruemmer, Section Editor)
  • Published:
Current Cardiology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

The current care model of type 2 diabetes (T2D) and its complications appears to be “asynchronous” with patient care divided by specialty. This model is associated with low use of guideline-directed medical therapies.

Recent Findings

The use of integrated care models has been well described in the management of patients with T2D; this usually includes an endocrinologist coupled with a nutritionist and nurse. However, physician-based care models are largely “asynchronous,” whereby the patient requires multiple different siloed specialties to manage their health care. To date, there has been limited exploration of synchronous care delivery, i.e., whereby multi-comorbid patients with T2D are seen simultaneously by health care providers from endocrinology, cardiology, and nephrology to optimize use of guideline-directed medical therapies (GDMT).

Summary

Given the rising complexity of patients with T2D, further research is needed on the role of synchronous health care delivery in optimizing the use of GDMT and improving patient outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. GBD 2015. Disease and injury incidence and prevalence collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1545–1602. https://doi.org/10.1016/S0140-6736(16)31678-6.

  2. From AM, et al. Diabetes in heart failure: prevalence and impact on outcome in the population. Am J Med. 2006;119(7):591–9.

    Article  Google Scholar 

  3. Thomas MC, Cooper ME, Zimmet P. Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease. Nat Rev Nephrol. 2016;12(2):73–81.

    Article  CAS  Google Scholar 

  4. Davies MJ, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41(12):2669–2701.

  5. Baena-Diez JM, et al. Risk of cause-specific death in individuals with diabetes: a competing risks analysis. Diabetes Care. 2016;39(11):1987–95.

    Article  Google Scholar 

  6. Sharma A, et al. Impact of regulatory guidance on evaluating cardiovascular risk of new glucose-lowering therapies to treat type 2 diabetes mellitus. Circulation. 2020;141:843–62.

    Article  Google Scholar 

  7. McGuire DK, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. JAMA Cardiol. 2021;6(2):148–58.

    Article  Google Scholar 

  8. Morton JI, et al. Projecting the incidence of type 2 diabetes-related end-stage kidney disease until 2040: a comparison between the effects of diabetes prevention and the effects of diabetes treatment. Diabetes Care. 2021.

  9. Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019;7(10):776–85.

    Article  CAS  Google Scholar 

  10. Schernthaner G, et al. Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes. Cardiovasc Diabetol. 2020;19(1):185.

    Article  Google Scholar 

  11. Eberly LA, et al. Association of race/ethnicity, gender, and socioeconomic status with sodium glucose cotransporter 2 inhibitor use among patients with diabetes in the US. JAMA Netw Open. 2021;4(4): e216139. https://doi.org/10.1001/jamanetworkopen.2021.6139.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Harrington DW, Wilson K, Rosenberg MW. Waiting for a specialist consultation for a new condition in Ontario: impacts on patients’ lives. Health Policy. 2014;9(4):90–103.

    Google Scholar 

  13. Keely E, Traczyk L, Liddy C. Patients’ perspectives on wait times and the referral-consultation process while attending a tertiary diabetes and endocrinology centre: is econsultation an acceptable option? Can J Diabetes. 2015;39(4):325–9.

    Article  Google Scholar 

  14. Liddy C, et al. How long are Canadians waiting to access specialty care? Retrospective study from a primary care perspective. Can Fam Physician. 2020;66(6):434–44.

    PubMed  PubMed Central  Google Scholar 

  15. Sanmartin C, Pierre F, Tremblay S. Waiting for care in Canada: findings from the health services access survey. Healthc Policy. 2006;2(2):43–51.

    PubMed  PubMed Central  Google Scholar 

  16. Arnold SV, et al. Use of guideline-recommended risk reduction strategies among patients with diabetes and atherosclerotic cardiovascular disease. Circulation. 2019;140(7):618–20.

    Article  Google Scholar 

  17. Arnold SV, et al. Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: an NCDR(R) Research to Practice project. Eur J Prev Cardiol. 2017;24(15):1637–45.

    Article  Google Scholar 

  18. Pantalone KM, et al. Antidiabetic treatment patterns and specialty care utilization among patients with type 2 diabetes and cardiovascular disease. Cardiovasc Diabetol. 2018;17(1):54.

    Article  Google Scholar 

  19. Reiter-Brennan C, et al. Comprehensive care models for cardiometabolic disease. Curr Cardiol Rep. 2021;23(3):22.

    Article  Google Scholar 

  20. •• Rangaswami J, Tuttle K, Vaduganathan M. Cardio-renal-metabolic care models: toward achieving effective interdisciplinary care. Circ Cardiovasc Qual Outcomes. 2020;13(11):e007264. Findings from this study suggest the pressing need for multidisciplinary care models called Cardio-Renal-Metabolic Models to improve the utilization of the effective medications that have shown to decrease mortality and cardiorenal complications.

  21. Dunlay SM, et al. Type 2 diabetes mellitus and heart failure: a scientific statement from the American Heart Association and the Heart Failure Society of America: This statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update. Circulation. 2019;140(7):e294–324.

    Article  CAS  Google Scholar 

  22. Kodner DL. All together now: a conceptual exploration of integrated care. Healthc Q. 2009;13:6–15.

    Article  Google Scholar 

  23. Specchia ML, et al. The impact of tumor board on cancer care: evidence from an umbrella review. BMC Health Serv Res. 2020;20(1):73.

    Article  Google Scholar 

  24. • Sharma A, et al. Permission to prescribe: do cardiologists need permission to prescribe diabetes medications that afford cardiovascular benefit? Curr Opin Cardiol. 2021;36(5):672–681. Findings from this study suggest the significant underutilization of the evidence-based oral hypoglycemic medications and how to overcome this obstacle. One of which is the multidisciplinary models of care.

  25. Lee DS, et al. Improved outcomes with early collaborative care of ambulatory heart failure patients discharged from the emergency department. Circulation. 2010;122(18):1806–14.

    Article  Google Scholar 

  26. McAlister FA, et al. A systematic review of randomized trials of disease management programs in heart failure. Am J Med. 2001;110(5):378–84.

    Article  CAS  Google Scholar 

  27. Phillips CO, et al. Comprehensive discharge planning with postdischarge support for older patients with congestive heart failure: a meta-analysis. JAMA. 2004;291(11):1358–67.

    Article  CAS  Google Scholar 

  28. Mavrakanas, T. The DECIDE-CV Cardiorenal Fellowship. 2021. Available from: https://www.mcgill.ca/pgme/files/pgme/fellowship_cardiorenal_research_july_2021_0.pdf. (Cited 2021 Oct 26).

  29. Cardiology, ACO. Succeed in managing cardiovascular risk in diabetes initiative. 2021. Available from: https://www.acc.org/tools-and-practice-support/quality-programs/cardiovascular-risk-in-diabetes-initiative. (Cited 2021 Oct 26).

  30. Sharma A, et al. Cluster analysis of cardiovascular phenotypes in patients with type 2 diabetes and established atherosclerotic cardiovascular disease: a potential approach to precision medicine. Diabetes Care. 2022;45(1):204–12.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Internal Medicine, McGill University Health Centre, McGill University, Montreal, QC, Canada

    Mohammad Alqahtani & Elie Ganni

  2. Division of Cardiology, McGill University Health Centre, Montreal, QC, Canada

    Abhinav Sharma

  3. DREAM-CV Lab, McGill University Health Centre Research Institute, McGill University, Montreal, QC, Canada

    Antonina Pavilanis, Julian Guida, Amir Razaghizad & Abhinav Sharma

  4. Division of Endocrinology and Metabolism, Jewish General Hospital, McGill University, Montreal, QC, Canada

    Tricia Peters

  5. Division of Endocrinology and Metabolism, McGill University Health Center, McGill University, Montreal, QC, Canada

    Michael Tsoukas & I. George Fantus

  6. Division of Nephrology, McGill University Health Center, McGill University, Montreal, QC, Canada

    Thomas Mavrakanas & Rita Suri

  7. McGill University Health Centre, 1001 Decarie Blvd, Montreal, QC, H4A 3J1, Canada

    Abhinav Sharma

Authors
  1. Mohammad Alqahtani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elie Ganni
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Thomas Mavrakanas
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michael Tsoukas
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tricia Peters
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Rita Suri
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. I. George Fantus
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Antonina Pavilanis
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Julian Guida
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Amir Razaghizad
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Abhinav Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Abhinav Sharma.

Ethics declarations

Conflict of Interest

AS reports receiving support from the Canada Institute for Health Research – 175095; Fonds de Recherche Santé Quebec (FRSQ) Junior 1 clinician scholars’ program, Alberta Innovates Health Solution, European Society of Cardiology young investigator grant, Roche Diagnostics, Boehringer-Ingelheim, Novartis, Takeda, AstraZeneca, Medtronic, Boston Scientific, and Novo-Nordisk. AS acknowledges support from the McGill University Health Centre (MUHC) Foundation, Montreal General Hospital (MGH) Foundation, Sarah Louise King Award, Marjorie Cadham Award, Inez and Willena Beaton award. TM received honoraria from Daiichi Sankyo, BMS Canada, Janssen, and Pfizer and has served on advisory boards for Boehringer Ingelheim, outside the submitted work. He is supported from the Fonds de Recherche Santé Quebec (FRSQ) Junior 1 clinician scholar program. TP is supported by the Fonds de Recherche Santé Quebec (FRSQ) Junior 1 clinician scholars’ program. MT reports personal fees from Boehringer-Ingelheim, AstraZeneca, Janssen, NovoNordisk, and Eli Lilly, outside the submitted work. RS reports other from Amgen, AstraZeneca, Otsuka, and Bayer, outside the submitted work. The other authors have nothing to disclose.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Diabetes and Cardiovascular Disease

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Alqahtani, M., Ganni, E., Mavrakanas, T. et al. Synchronous Health Care Delivery for the Optimization of Cardiovascular and Renal Care in Patients with Type 2 Diabetes. Curr Cardiol Rep 24, 979–985 (2022). https://doi.org/10.1007/s11886-022-01715-3

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11886-022-01715-3

Keywords

Search

Navigation